{"id":"NCT03056040","sponsor":"Alexion Pharmaceuticals, Inc.","briefTitle":"ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","officialTitle":"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-17","primaryCompletion":"2022-02-21","completion":"2022-02-21","firstPosted":"2017-02-16","resultsPosted":"2019-03-21","lastUpdate":"2025-03-12"},"enrollment":202,"design":{"allocation":"NA","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria (PNH)"],"interventions":[{"type":"BIOLOGICAL","name":"Ravulizumab","otherNames":["ALXN1210","ULTOMIRIS"]},{"type":"BIOLOGICAL","name":"Eculizumab","otherNames":[]}],"arms":[{"label":"Ravulizumab","type":"EXPERIMENTAL"},{"label":"Eculizumab","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who were clinically stable after having been treated with eculizumab for at least 6 months.","primaryOutcome":{"measure":"Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183","timeFrame":"Baseline, Day 183","effectByArm":[{"arm":"Ravulizumab/Ravulizumab","deltaMin":-0.82,"sd":null},{"arm":"Eculizumab/Ravulizumab","deltaMin":8.39,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":51,"countries":["United States","Australia","Canada","France","Germany","Italy","Japan","Netherlands","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["30510079","31949012","32869125","35502600","33301613","32449174","33178408","39841198","34526067"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=ALXN1210-PNH-302&amp;attachmentIdentifier=c826be5c-044d-4dab-9e62-2d48684248c7&amp;fileName=ALXN1210-PNH-302-CSR_Synopsis_redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":97},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Fatigue","Nausea"]}}